ABROCITINIB

Information current as at: 1 May 2024

PBAC meeting date: November 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Cibinqo®
Pharmaceutical company:
Pfizer Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Atopic dermatitis
PBAC Submission type:
New listing (–)
Comment:
To be considered at a future PBAC meeting
Related medicines:
--

Progress Details

Submission received for:
November 2021 PBAC meeting
Opportunity for consumer comment:
Open 28/07/2021 and close 22/09/2021 (see PBS Website)
PBAC meeting:
Not applicable
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a389

Page last updated: 02 May 2024

v.9.18